Long-term Extension of GTX-102 in Angelman Syndrome
Clinical trial NCT06415344 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT06415344
- Sponsor
- Ultragenyx Pharmaceutical Inc
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-31
- Primary completion
- 2029-02-01
- Enrollment
- 255
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.